Cash Flow Statement (Annual)
AEL / American Equity Investment Life Holding Co. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities Continuing Operations|
|Net Income Loss||68,530||42,933||86,248||57,798||253,283||126,023||219,830||83,243||174,645|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Interest Sensitive And Index Product Benefits||347,883||733,218||775,757||808,479||1,272,867||1,473,700||968,053||725,472||2,023,668|
|Deferred Sales Inducements Amortization Expense||39,999||59,873||71,781||87,157||253,113||131,419||209,390||251,166||176,612|
|Insurance Commissions And Fees||-||-||76,189||89,006||103,591||118,990||136,168||173,579||200,494|
|Embedded Derivative Gain Loss On Embedded Derivative Net||-529,508||-130,950||105,194||-286,899||-133,968||-32,321||464,698||-543,465||-919,735|
|Increase Decrease In Insurance Liabilities||9,960||43,921||76,220||35,758||14,997||2,385||5,097||12,724||-33|
|Increase Decrease In Deferred Policy Acquisition Costs||-||-||-||-||-||426,882||657,639||543,325||406,641|
|Deferred Policy Acquisition Cost Amortization Expense||88,009||136,388||143,478||164,919||365,468||163,578||286,114||374,012||255,964|
|Other Depreciation And Amortization||-||-||-||-||18,375||9,490||4,610||3,879||3,948|
|Accretion Amortization Of Discounts And Premiums Investments||212,498||240,532||154,483||69,828||-6,861||14,960||8,464||-1,070||-15,431|
|Gain Loss On Investments||-35,492||-141||-52,617||-21,386||34,327||-6,630||-9,325||-11,155||5,879|
|Equity Method Investment Dividends Or Distributions||-||-||-||-||-||-||-||-||-|
|Gain Loss On Derivative Instruments Net Pretax||219,154||141,719||-112,608||221,138||1,076,015||506,328||-334,300||165,727||1,678,956|
|Deferred Income Tax Expense Benefit||-56,150||-118,048||-80,869||-52,336||3,013||-46,504||41,916||-10,408||-46,730|
|Gains Losses On Extinguishment Of Debt||-675||-292||0||0||-32,515||-12,502||0||0||-18,817|
|Share Based Compensation||4,630||11,993||9,339||6,552||10,476||3,544||7,373||6,692||6,464|
|Increase Decrease In Accrued Investment Income Receivable||21,902||53,987||61,292||32,896||39,808||24,918||35,545||35,669||31,235|
|Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable||117,817||-97,550||2,307||13,197||5,397||-19,405||-20,027||18,125||45,759|
|Increase Decrease In Other Operating Assets||10,877||26,516||-5,005||7,090||-1,113||2,771||-71||-1,812||-448|
|Increase Decrease In Other Policyholder Funds||8,198||103,457||177,734||55,158||-47,445||-60,931||-49,092||-34,411||-23,101|
|Increase Decrease Cash Collateral From Counterparties||-||-||-||-||-||-||-269,474||414,655||772,181|
|Increase Decrease In Other Operating Liabilities||40,637||64,776||-77,082||5,927||-11,435||-51,008||75,794||-55,940||-84,416|
|Increase Decrease In Other Operating Capital Net||1,759||-812||-59||857||7,059||8,948||15,962||14,089||13,794|
|Net Cash Provided By Used In Operating Activities||516,551||420,475||277,791||784,314||862,668||707,786||504,804||1,414,322||1,922,393|
|Net Cash Provided By Used In Investing Activities|
|Proceeds From Sale Maturity And Collections Of Investments|
|Proceeds From Sale And Maturity Of Available For Sale Securities||-||-||-||-||-||-||-||-||-|
|Proceeds From Sale And Collection Of Mortgage Notes Receivable||109,969||145,754||206,741||543,211||539,240||453,937||468,102||383,763||351,255|
|Proceeds From Derivative Instrument Investing Activities||79,341||492,058||506,057||483,362||971,432||1,169,874||640,467||284,470||1,697,948|
|Proceeds From Sale And Maturity Of Other Investments||-||0||2,274||33,601||24,050||23,165||16,792||14,045||10,571|
|Payments To Acquire Investments|
|Payments To Acquire Available For Sale Securities Debt||6,742,292||8,544,788||5,347,839||8,266,692||7,962,150||5,191,781||7,256,137||6,883,895||5,026,640|
|Payments To Acquire Mortgage Notes Receivable||249,162||317,250||481,680||386,507||505,953||327,654||455,286||428,833||535,249|
|Payments For Derivative Instrument Investing Activities||257,435||331,263||395,938||379,592||419,345||492,296||588,859||602,349||691,428|
|Payments To Acquire Other Investments||46||456||77,955||86,569||29,015||72,548||13,092||11,559||305,575|
|Payments To Acquire Property Plant And Equipment||2,971||5,318||5,265||738||948||1,352||1,313||1,197||4,809|
|Net Cash Provided By Used In Investing Activities||-2,013,730||-3,116,388||-3,605,833||-2,129,490||-3,879,296||-2,947,749||-5,577,205||-4,499,045||-2,591,936|
|Net Cash Provided By Used In Financing Activities|
|Proceeds From Annuities And Investment Certificates||3,677,558||4,497,091||4,784,511||3,782,275||4,160,346||4,160,005||7,051,227||7,092,348||4,152,264|
|Increase Decrease In Reinsurance Recoverable||-||-||-||-||-||-||80,777||1,317,555||6,597|
|Repayments Of Annuities And Investment Certificates||1,418,797||1,465,434||1,494,554||1,575,340||1,763,913||2,025,203||2,271,950||2,535,669||2,809,486|
|Payments Of Financing Costs||2,751||6,800||1,566||0||11,942||100||0||1,456||5,817|
|Proceeds From Issuance Of Unsecured Debt||-||-||-||-||-||0||0||0||499,650|
|Repayments Of Other Long Term Debt||-||-||-||-||-||-||0||0||100,000|
|Proceeds From Payments For In Securities Sold Under Agreements To Repurchase||-||-||-||-||-||-||-||-||-|
|Proceeds From Issuance Of Common Stock||1,061||6,124||4,686||5,741||31,764||13,681||112,481||139,654||14,028|
|Increase Decrease In Outstanding Checks Financing Activities||-8,605||-13,238||17,156||1,071||9,212||-1,252||-5,727||21,501||4,680|
|Net Cash Provided By Used In Financing Activities||1,810,319||2,765,677||3,135,228||2,208,769||2,645,612||2,043,948||4,768,636||3,478,240||1,312,322|
|Cash And Cash Equivalents Period Increase Decrease||313,140||69,764||-192,814||863,593||-371,016||-196,015||-303,765||393,517||642,779|
|Cash And Cash Equivalents At Carrying Value||-||-||-||-||-||701,514||397,749||791,266||1,434,045|
|Supplemental Cash Flow Information|
|Income Taxes Paid Net|
|Income Taxes Paid||191,878||143,748||129,250||67,450||128,225||132,754||91,887||39,066||142,627|
|Non Cash Operating Activity|
|Deferred Sales Inducements Additions||292,791||370,714||385,123||306,659||337,787||330,079||486,924||353,966||216,172|
Peers - Life Insurance (6311)
EMG / Emergent Capital, Inc.
FFG / FBL Financial Group, Inc.
FGL / Fidelity & Guaranty Life
GNW / Genworth Financial, Inc.
IHC / Independence Holding Co.
LNC / Lincoln National Corp.
MET / MetLife, Inc.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET